Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 245

1.

Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology.

Went M, Sud A, Speedy H, Sunter NJ, Försti A, Law PJ, Johnson DC, Mirabella F, Holroyd A, Li N, Orlando G, Weinhold N, van Duin M, Chen B, Mitchell JS, Mansouri L, Juliusson G, Smedby KE, Jayne S, Majid A, Dearden C, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Rosenquist R, Kuiper R, Stephens OW, Bertsch U, Broderick P, Einsele H, Gregory WM, Hillengass J, Hoffmann P, Jackson GH, Jöckel KH, Nickel J, Nöthen MM, da Silva Filho MI, Thomsen H, Walker BA, Broyl A, Davies FE, Hansson M, Goldschmidt H, Dyer MJS, Kaiser M, Sonneveld P, Morgan GJ, Hemminki K, Nilsson B, Catovsky D, Allan JM, Houlston RS.

Blood Cancer J. 2018 Dec 21;9(1):1. doi: 10.1038/s41408-018-0162-8.

2.

Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia.

Baliakas P, Moysiadis T, Hadzidimitriou A, Xochelli A, Jeromin S, Agathangelidis A, Mattsson M, Sutton LA, Minga E, Scarfò L, Rossi D, Davis Z, Villamor N, Parker H, Kotaskova J, Stalika E, Plevova K, Mansouri L, Cortese D, Navarro A, Delgado J, Larrayoz M, Young E, Anagnostopoulos A, Smedby KE, Juliusson G, Sheehy O, Catherwood M, Strefford JC, Stavroyianni N, Belessi C, Pospisilova S, Oscier D, Gaidano G, Campo E, Haferlach C, Ghia P, Rosenquist R, Stamatopoulos K; European Research Initiative on CLL (ERIC).

Haematologica. 2019 Feb;104(2):360-369. doi: 10.3324/haematol.2018.195032. Epub 2018 Sep 27.

3.

A platform for phenotypic discovery of therapeutic antibodies and targets applied on Chronic Lymphocytic Leukemia.

Ljungars A, Mårtensson L, Mattsson J, Kovacek M, Sundberg A, Tornberg UC, Jansson B, Persson N, Emruli VK, Ek S, Jerkeman M, Hansson M, Juliusson G, Ohlin M, Frendéus B, Teige I, Mattsson M.

NPJ Precis Oncol. 2018 Sep 3;2:18. doi: 10.1038/s41698-018-0061-2. eCollection 2018.

4.

A new genetic tool to improve immune-compromised mouse models: Derivation and CRISPR/Cas9-mediated targeting of NRG embryonic stem cell lines.

Martin Gonzalez J, Baudet A, Abelechian S, Bonderup K, d'Altri T, Porse B, Brakebusch C, Juliusson G, Cammenga J.

Genesis. 2018 Sep;56(9):e23238. doi: 10.1002/dvg.23238.

PMID:
30010246
5.

Acute myeloid leukemia in very old patients.

Lazarevic VL, Bredberg A, Lorenz F, Ölander E, Antunovic P, Cammenga J, Wennström L, Möllgård L, Deneberg S, Derolf Å, Höglund M, Juliusson G.

Haematologica. 2018 Jun 28. pii: haematol.2018.196691. doi: 10.3324/haematol.2018.196691. [Epub ahead of print] No abstract available.

6.

Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NFκB-dependent differentiation of AML cells.

Eriksson M, Peña-Martínez P, Ramakrishnan R, Chapellier M, Högberg C, Glowacki G, Orsmark-Pietras C, Velasco-Hernández T, Lazarević VL, Juliusson G, Cammenga J, Mulloy JC, Richter J, Fioretos T, Ebert BL, Järås M.

Blood Adv. 2017 Oct 18;1(23):2046-2057. doi: 10.1182/bloodadvances.2017006148. eCollection 2017 Oct 24.

7.

No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy.

Baliakas P, Mattsson M, Hadzidimitriou A, Minga E, Agathangelidis A, Sutton LA, Scarfo L, Davis Z, Yan XJ, Plevova K, Sandberg Y, Vojdeman FJ, Tzenou T, Chu CC, Veronese S, Mansouri L, Smedby KE, Giudicelli V, Nguyen-Khac F, Panagiotidis P, Juliusson G, Anagnostopoulos A, Lefranc MP, Trentin L, Catherwood M, Montillo M, Niemann CU, Langerak AW, Pospisilova S, Stavroyianni N, Chiorazzi N, Oscier D, Jelinek DF, Shanafelt T, Darzentas N, Belessi C, Davi F, Ghia P, Rosenquist R, Stamatopoulos K.

Haematologica. 2018 Apr;103(4):e158-e161. doi: 10.3324/haematol.2017.182634. Epub 2017 Dec 21. No abstract available.

8.

Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry.

Blimark CH, Turesson I, Genell A, Ahlberg L, Björkstrand B, Carlson K, Forsberg K, Juliusson G, Linder O, Mellqvist UH, Nahi H, Kristinsson SY; Swedish Myeloma Registry.

Haematologica. 2018 Mar;103(3):506-513. doi: 10.3324/haematol.2017.178103. Epub 2017 Dec 7.

9.

Isolated myelosarcoma is characterized by recurrent NFE2 mutations and concurrent preleukemic clones in the bone marrow.

Lazarevic V, Orsmark-Pietras C, Lilljebjörn H, Pettersson L, Rissler M, Lübking A, Ehinger M, Juliusson G, Fioretos T.

Blood. 2018 Feb 1;131(5):577-581. doi: 10.1182/blood-2017-07-793620. Epub 2017 Nov 30. No abstract available.

10.

Incidence, diagnostic, treatment and outcome of patients diagnosed with cancer of the pancreas during 1986-2009: a population-based study.

Jonsdottir SB, Juliusson G, Kristinsson JÖ, Hreinsson JP, Jonasson JG, Björnsson ES.

Scand J Gastroenterol. 2018 Jan;53(1):100-106. doi: 10.1080/00365521.2017.1390598. Epub 2017 Oct 23.

PMID:
29058490
11.

Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia.

Anguille S, Van de Velde AL, Smits EL, Van Tendeloo VF, Juliusson G, Cools N, Nijs G, Stein B, Lion E, Van Driessche A, Vandenbosch I, Verlinden A, Gadisseur AP, Schroyens WA, Muylle L, Vermeulen K, Maes MB, Deiteren K, Malfait R, Gostick E, Lammens M, Couttenye MM, Jorens P, Goossens H, Price DA, Ladell K, Oka Y, Fujiki F, Oji Y, Sugiyama H, Berneman ZN.

Blood. 2017 Oct 12;130(15):1713-1721. doi: 10.1182/blood-2017-04-780155. Epub 2017 Aug 22.

12.

Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register.

Nahi H, Genell A, Wålinder G, Uttervall K, Juliusson G, Karin F, Hansson M, Svensson R, Linder O, Carlson K, Björkstrand B, Kristinsson SY, Mellqvist UH, Blimark C, Turesson I.

Eur J Haematol. 2017 Sep;99(3):216-222. doi: 10.1111/ejh.12907. Epub 2017 Jun 28.

PMID:
28544116
13.

Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes.

Xochelli A, Baliakas P, Kavakiotis I, Agathangelidis A, Sutton LA, Minga E, Ntoufa S, Tausch E, Yan XJ, Shanafelt T, Plevova K, Boudjogra M, Rossi D, Davis Z, Navarro A, Sandberg Y, Vojdeman FJ, Scarfo L, Stavroyianni N, Sudarikov A, Veronese S, Tzenou T, Karan-Djurasevic T, Catherwood M, Kienle D, Chatzouli M, Facco M, Bahlo J, Pott C, Pedersen LB, Mansouri L, Smedby KE, Chu CC, Giudicelli V, Lefranc MP, Panagiotidis P, Juliusson G, Anagnostopoulos A, Vlahavas I, Antic D, Trentin L, Montillo M, Niemann C, Döhner H, Langerak AW, Pospisilova S, Hallek M, Campo E, Chiorazzi N, Maglaveras N, Oscier D, Gaidano G, Jelinek DF, Stilgenbauer S, Chouvarda I, Darzentas N, Belessi C, Davi F, Hadzidimitriou A, Rosenquist R, Ghia P, Stamatopoulos K.

Clin Cancer Res. 2017 Sep 1;23(17):5292-5301. doi: 10.1158/1078-0432.CCR-16-3100. Epub 2017 May 23.

14.

Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997-2013.

Lehmann S, Deneberg S, Antunovic P, Rangert-Derolf Å, Garelius H, Lazarevic V, Myhr-Eriksson K, Möllgård L, Uggla B, Wahlin A, Wennström L, Höglund M, Juliusson G.

Leukemia. 2017 Jun;31(6):1457-1459. doi: 10.1038/leu.2017.71. Epub 2017 Feb 24. No abstract available.

PMID:
28232742
15.

A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma.

Wichert S, Juliusson G, Johansson Å, Sonesson E, Teige I, Wickenberg AT, Frendeus B, Korsgren M, Hansson M.

PLoS One. 2017 Feb 3;12(2):e0171205. doi: 10.1371/journal.pone.0171205. eCollection 2017.

16.

Incidence and prognostic significance of isolated trisomies in adult acute myeloid leukemia: A population-based study from the Swedish AML registry.

Lazarevic VL, Rosso A, Juliusson G, Antunovic P, Derolf ÅR, Deneberg S, Möllgård L, Uggla B, Wennström L, Wahlin A, Höglund M, Lehmann S, Johansson B.

Eur J Haematol. 2017 May;98(5):493-500. doi: 10.1111/ejh.12861. Epub 2017 Mar 9.

PMID:
28152233
17.

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.

Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B.

Blood. 2017 Feb 2;129(5):553-560. doi: 10.1182/blood-2016-01-689422. Epub 2016 Nov 30.

18.

EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.

Young E, Noerenberg D, Mansouri L, Ljungström V, Frick M, Sutton LA, Blakemore SJ, Galan-Sousa J, Plevova K, Baliakas P, Rossi D, Clifford R, Roos-Weil D, Navrkalova V, Dörken B, Schmitt CA, Smedby KE, Juliusson G, Giacopelli B, Blachly JS, Belessi C, Panagiotidis P, Chiorazzi N, Davi F, Langerak AW, Oscier D, Schuh A, Gaidano G, Ghia P, Xu W, Fan L, Bernard OA, Nguyen-Khac F, Rassenti L, Li J, Kipps TJ, Stamatopoulos K, Pospisilova S, Zenz T, Oakes CC, Strefford JC, Rosenquist R, Damm F.

Leukemia. 2017 Jul;31(7):1547-1554. doi: 10.1038/leu.2016.359. Epub 2016 Nov 28.

PMID:
27890934
19.

Prevalence and characteristics of survivors from acute myeloid leukemia in Sweden.

Juliusson G, Abrahamsson J, Lazarevic V, Antunovic P, Derolf Å, Garelius H, Lehmann S, Myhr-Eriksson K, Möllgård L, Uggla B, Wahlin A, Wennström L, Höglund M; Swedish AML Group and the Swedish Childhood Leukemia Group.

Leukemia. 2017 Mar;31(3):728-731. doi: 10.1038/leu.2016.312. Epub 2016 Oct 31. No abstract available.

20.

Leukemia.

Juliusson G, Hough R.

Prog Tumor Res. 2016;43:87-100. doi: 10.1159/000447076. Epub 2016 Sep 5. Review.

PMID:
27595359
21.

Biliary tract malignancies: a population-based study on incidence, prognosis and management of patients.

Juliusson G, Jonasson JG, Jonsdottir SB, Garcia HG, Olafsdottir E, Möller PH, Björnsson ES.

Scand J Gastroenterol. 2016 Dec;51(12):1520-1525. Epub 2016 Aug 24.

PMID:
27553174
22.

ATM mutations in major stereotyped subsets of chronic lymphocytic leukemia: enrichment in subset #2 is associated with markedly short telomeres.

Navrkalova V, Young E, Baliakas P, Radova L, Sutton LA, Plevova K, Mansouri L, Ljungström V, Ntoufa S, Davis Z, Juliusson G, Smedby KE, Belessi C, Panagiotidis P, Touloumenidou T, Davi F, Langerak AW, Ghia P, Strefford JC, Oscier D, Mayer J, Stamatopoulos K, Pospisilova S, Rosenquist R, Trbusek M.

Haematologica. 2016 Sep;101(9):e369-73. doi: 10.3324/haematol.2016.142968. Epub 2016 Jun 16. No abstract available.

23.

Subpopulations of T Regulatory Cells in Blood Stem Cell Harvests Influence Development of Acute Graft Versus Host Disease in Allogeneic Transplant Recipients.

Roschupkina T, Juliusson G.

Cytometry B Clin Cytom. 2018 Mar;94(2):264-269. doi: 10.1002/cyto.b.21404. Epub 2016 Aug 29.

PMID:
27479496
24.

An open-label phase I dose-finding study of APR-246 in hematological malignancies.

Deneberg S, Cherif H, Lazarevic V, Andersson PO, von Euler M, Juliusson G, Lehmann S.

Blood Cancer J. 2016 Jul 15;6(7):e447. doi: 10.1038/bcj.2016.60. No abstract available.

25.

Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia.

Pettersson L, Levéen P, Axler O, Dvorakova D, Juliusson G, Ehinger M.

Genes Chromosomes Cancer. 2016 Oct;55(10):750-66. doi: 10.1002/gcc.22375. Epub 2016 Jun 24.

PMID:
27191933
26.

Prognostic impact of epigenetic classification in chronic lymphocytic leukemia: The case of subset #2.

Bhoi S, Ljungström V, Baliakas P, Mattsson M, Smedby KE, Juliusson G, Rosenquist R, Mansouri L.

Epigenetics. 2016 Jun 2;11(6):449-55. doi: 10.1080/15592294.2016.1178432. Epub 2016 Apr 29.

27.

Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis.

Juliusson G, Imam M, Björnsson ES, Talwalkar JA, Lindor KD.

Scand J Gastroenterol. 2016;51(6):745-52. doi: 10.3109/00365521.2015.1132337. Epub 2016 Jan 18.

PMID:
26776319
28.

Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.

Ljungström V, Cortese D, Young E, Pandzic T, Mansouri L, Plevova K, Ntoufa S, Baliakas P, Clifford R, Sutton LA, Blakemore SJ, Stavroyianni N, Agathangelidis A, Rossi D, Höglund M, Kotaskova J, Juliusson G, Belessi C, Chiorazzi N, Panagiotidis P, Langerak AW, Smedby KE, Oscier D, Gaidano G, Schuh A, Davi F, Pott C, Strefford JC, Trentin L, Pospisilova S, Ghia P, Stamatopoulos K, Sjöblom T, Rosenquist R.

Blood. 2016 Feb 25;127(8):1007-16. doi: 10.1182/blood-2015-10-674572. Epub 2015 Dec 16.

29.

UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia?

Bhoi S, Baliakas P, Cortese D, Mattsson M, Engvall M, Smedby KE, Juliusson G, Sutton LA, Mansouri L.

Haematologica. 2016 Feb;101(2):e63-5. doi: 10.3324/haematol.2015.136440. Epub 2015 Nov 20. No abstract available.

30.

Small molecule screen identifies differentiation-promoting compounds targeting genetically diverse acute myeloid leukaemia.

Baudet A, Ek F, Davidsson J, Soneji S, Olsson R, Magnusson M, Cammenga J, Juliusson G.

Br J Haematol. 2016 Oct;175(2):342-346. doi: 10.1111/bjh.13851. Epub 2015 Nov 16. No abstract available.

PMID:
26567888
31.

No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine.

Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner BP, Marta M, Juliusson G, Baker D, Chataway J, Schmierer K.

Neurol Neuroimmunol Neuroinflamm. 2015 Oct 1;2(6):e158. doi: 10.1212/NXI.0000000000000158. eCollection 2015 Dec.

32.

Acute Myeloid Leukemia in Adolescents and Young Adults Treated in Pediatric and Adult Departments in the Nordic Countries.

Wennström L, Edslev PW, Abrahamsson J, Nørgaard JM, Fløisand Y, Forestier E, Gustafsson G, Heldrup J, Hovi L, Jahnukainen K, Jonsson OG, Lausen B, Palle J, Zeller B, Holmberg E, Juliusson G, Stockelberg D, Hasle H; Nordic Society of Paediatric Haematology and Oncology (NOPHO); Danish Acute Leukemia Group; Swedish Acute Myeloid Leukemia Group.

Pediatr Blood Cancer. 2016 Jan;63(1):83-92. doi: 10.1002/pbc.25713. Epub 2015 Aug 18.

PMID:
26281822
33.

Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.

Ågerstam H, Karlsson C, Hansen N, Sandén C, Askmyr M, von Palffy S, Högberg C, Rissler M, Wunderlich M, Juliusson G, Richter J, Sjöström K, Bhatia R, Mulloy JC, Järås M, Fioretos T.

Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):10786-91. doi: 10.1073/pnas.1422749112. Epub 2015 Aug 10.

34.

Frequent and long-term follow-up of health-related quality of life following allogeneic haematopoietic stem cell transplantation.

Frödin U, Lotfi K, Fomichov V, Juliusson G, Börjeson S.

Eur J Cancer Care (Engl). 2015 Nov;24(6):898-910. doi: 10.1111/ecc.12350. Epub 2015 Jul 7.

35.

Prognostic significance of high hyperdiploid and triploid/tetraploid adult acute myeloid leukemia.

Lazarevic V, Rosso A, Juliusson G, Antunovic P, Rangert-Derolf Å, Lehmann S, Möllgård L, Uggla B, Wennström L, Wahlin A, Höglund M, Johansson B.

Am J Hematol. 2015 Sep;90(9):800-5. doi: 10.1002/ajh.24091. Epub 2015 Jul 22.

36.

Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia.

Mansouri L, Sutton LA, Ljungström V, Bondza S, Arngården L, Bhoi S, Larsson J, Cortese D, Kalushkova A, Plevova K, Young E, Gunnarsson R, Falk-Sörqvist E, Lönn P, Muggen AF, Yan XJ, Sander B, Enblad G, Smedby KE, Juliusson G, Belessi C, Rung J, Chiorazzi N, Strefford JC, Langerak AW, Pospisilova S, Davi F, Hellström M, Jernberg-Wiklund H, Ghia P, Söderberg O, Stamatopoulos K, Nilsson M, Rosenquist R.

J Exp Med. 2015 Jun 1;212(6):833-43. doi: 10.1084/jem.20142009. Epub 2015 May 18.

37.

Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo.

Roghanian A, Teige I, Mårtensson L, Cox KL, Kovacek M, Ljungars A, Mattson J, Sundberg A, Vaughan AT, Shah V, Smyth NR, Sheth B, Chan HT, Li ZC, Williams EL, Manfredi G, Oldham RJ, Mockridge CI, James SA, Dahal LN, Hussain K, Nilsson B, Verbeek JS, Juliusson G, Hansson M, Jerkeman M, Johnson PW, Davies A, Beers SA, Glennie MJ, Frendéus B, Cragg MS.

Cancer Cell. 2015 Apr 13;27(4):473-88. doi: 10.1016/j.ccell.2015.03.005.

38.

Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, Nordic and Turkish myeloma study groups.

Beksac M, Waage A, Bringhen S, Kristinsson SY, Sucak GT, Gimsing P, Lupparelli G, Fıratlı-Tuğlular T, Juliusson G, Turesson I, Palumbo A.

Acta Haematol. 2015;133(4):372-80. doi: 10.1159/000370023. Epub 2015 Mar 24.

39.

A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe.

Giovannoni G, de Jong B, Derfuss T, Izquierdo G, Mazibrada G, Molyneux P, Nicholas R, Overell J, Ziemssen T, Juliusson G.

Mult Scler Relat Disord. 2015 Jan;4(1):83-4. doi: 10.1016/j.msard.2014.09.215. Epub 2014 Oct 13. No abstract available.

PMID:
25787058
40.

Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations.

Baliakas P, Agathangelidis A, Hadzidimitriou A, Sutton LA, Minga E, Tsanousa A, Scarfò L, Davis Z, Yan XJ, Shanafelt T, Plevova K, Sandberg Y, Vojdeman FJ, Boudjogra M, Tzenou T, Chatzouli M, Chu CC, Veronese S, Gardiner A, Mansouri L, Smedby KE, Pedersen LB, Moreno D, Van Lom K, Giudicelli V, Francova HS, Nguyen-Khac F, Panagiotidis P, Juliusson G, Angelis L, Anagnostopoulos A, Lefranc MP, Facco M, Trentin L, Catherwood M, Montillo M, Geisler CH, Langerak AW, Pospisilova S, Chiorazzi N, Oscier D, Jelinek DF, Darzentas N, Belessi C, Davi F, Ghia P, Rosenquist R, Stamatopoulos K.

Blood. 2015 Jan 29;125(5):856-9. doi: 10.1182/blood-2014-09-600874. Epub 2014 Dec 17.

41.

Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry.

Hulegårdh E, Nilsson C, Lazarevic V, Garelius H, Antunovic P, Rangert Derolf Å, Möllgård L, Uggla B, Wennström L, Wahlin A, Höglund M, Juliusson G, Stockelberg D, Lehmann S.

Am J Hematol. 2015 Mar;90(3):208-14. doi: 10.1002/ajh.23908. Epub 2015 Jan 16.

42.

Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk.

Sava GP, Speedy HE, Di Bernardo MC, Dyer MJ, Holroyd A, Sunter NJ, Marr H, Mansouri L, Deaglio S, Karabon L, Frydecka I, Jamroziak K, Woszczyk D, Juliusson G, Smedby KE, Jayne S, Majid A, Wang Y, Dearden C, Hall AG, Mainou-Fowler T, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Rosenquist R, Catovsky D, Allan JM, Houlston RS.

Leukemia. 2015 Mar;29(3):748-51. doi: 10.1038/leu.2014.311. Epub 2014 Nov 3. No abstract available.

43.

Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study.

Baliakas P, Hadzidimitriou A, Sutton LA, Minga E, Agathangelidis A, Nichelatti M, Tsanousa A, Scarfò L, Davis Z, Yan XJ, Shanafelt T, Plevova K, Sandberg Y, Vojdeman FJ, Boudjogra M, Tzenou T, Chatzouli M, Chu CC, Veronese S, Gardiner A, Mansouri L, Smedby KE, Pedersen LB, van Lom K, Giudicelli V, Francova HS, Nguyen-Khac F, Panagiotidis P, Juliusson G, Angelis L, Anagnostopoulos A, Lefranc MP, Facco M, Trentin L, Catherwood M, Montillo M, Geisler CH, Langerak AW, Pospisilova S, Chiorazzi N, Oscier D, Jelinek DF, Darzentas N, Belessi C, Davi F, Rosenquist R, Ghia P, Stamatopoulos K.

Lancet Haematol. 2014 Nov;1(2):e74-84. doi: 10.1016/S2352-3026(14)00005-2. Epub 2014 Nov 3.

PMID:
27030157
44.

Failure matters: unsuccessful cytogenetics and unperformed cytogenetics are associated with a poor prognosis in a population-based series of acute myeloid leukaemia.

Lazarevic V, Hörstedt AS, Johansson B, Antunovic P, Billström R, Derolf Å, Lehmann S, Möllgård L, Peterson S, Stockelberg D, Uggla B, Vennström L, Wahlin A, Höglund M, Juliusson G.

Eur J Haematol. 2015 May;94(5):419-23. doi: 10.1111/ejh.12446. Epub 2014 Oct 3.

PMID:
25200361
45.

Recurrent mutations refine prognosis in chronic lymphocytic leukemia.

Baliakas P, Hadzidimitriou A, Sutton LA, Rossi D, Minga E, Villamor N, Larrayoz M, Kminkova J, Agathangelidis A, Davis Z, Tausch E, Stalika E, Kantorova B, Mansouri L, Scarfò L, Cortese D, Navrkalova V, Rose-Zerilli MJ, Smedby KE, Juliusson G, Anagnostopoulos A, Makris AM, Navarro A, Delgado J, Oscier D, Belessi C, Stilgenbauer S, Ghia P, Pospisilova S, Gaidano G, Campo E, Strefford JC, Stamatopoulos K, Rosenquist R; European Research Initiative on CLL (ERIC).

Leukemia. 2015 Feb;29(2):329-36. doi: 10.1038/leu.2014.196. Epub 2014 Jun 19.

PMID:
24943832
46.

Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience.

Lazarevic V, Hörstedt AS, Johansson B, Antunovic P, Billström R, Derolf A, Hulegårdh E, Lehmann S, Möllgård L, Nilsson C, Peterson S, Stockelberg D, Uggla B, Wennström L, Wahlin A, Höglund M, Juliusson G.

Blood Cancer J. 2014 Feb 28;4:e188. doi: 10.1038/bcj.2014.10.

47.

Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia.

Mulligan SP, Karlsson K, Strömberg M, Jønsson V, Gill D, Hammerström J, Hertzberg M, McLennan R, Uggla B, Norman J, Wallvik J, Sundström G, Johansson H, Brandberg Y, Liliemark J, Juliusson G; Scandinavian and Australasian Leukaemia Lymphoma Groups (Allg).

Leuk Lymphoma. 2014 Dec;55(12):2769-77. doi: 10.3109/10428194.2014.893306. Epub 2014 Apr 16.

PMID:
24524339
48.

A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia.

Speedy HE, Di Bernardo MC, Sava GP, Dyer MJ, Holroyd A, Wang Y, Sunter NJ, Mansouri L, Juliusson G, Smedby KE, Roos G, Jayne S, Majid A, Dearden C, Hall AG, Mainou-Fowler T, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Rosenquist R, Catovsky D, Allan JM, Houlston RS.

Nat Genet. 2014 Jan;46(1):56-60. doi: 10.1038/ng.2843. Epub 2013 Dec 1.

PMID:
24292274
49.

Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.

Morabito F, Bringhen S, Larocca A, Wijermans P, Victoria Mateos M, Gimsing P, Mazzone C, Gottardi D, Omedè P, Zweegman S, José Lahuerta J, Zambello R, Musto P, Magarotto V, Schaafsma M, Oriol A, Juliusson G, Cerrato C, Catalano L, Gentile M, Isabel Turel A, Marina Liberati A, Cavalli M, Rossi D, Passera R, Rosso S, Beksac M, Cavo M, Waage A, San Miguel J, Boccadoro M, Sonneveld P, Palumbo A, Offidani M.

Am J Hematol. 2014 Apr;89(4):355-62. doi: 10.1002/ajh.23641. Epub 2014 Feb 5.

50.

On the way towards a 'CLL prognostic index': focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort.

Cortese D, Sutton LA, Cahill N, Smedby KE, Geisler C, Gunnarsson R, Juliusson G, Mansouri L, Rosenquist R.

Leukemia. 2014 Mar;28(3):710-3. doi: 10.1038/leu.2013.333. Epub 2013 Nov 12. No abstract available.

PMID:
24217197

Supplemental Content

Loading ...
Support Center